A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets.

Trial Profile

A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2017

At a glance

  • Drugs Metformin/sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 20 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 19 Mar 2014 Planned End Date changed from 1 Mar 2014 to 1 Sep 2014 according to ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top